Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson's disease

Antioxidants and Redox Signaling

Volumn 21, Issue 4, 2014, Pages 649-667

  Greene, James G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE;

BRAIN REGION; BRAIN STEM; CENTRAL NERVOUS SYSTEM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GASTROINTESTINAL TRACT; HUMAN; INFLAMMATION; MESENCEPHALON; MOTONEURON NUCLEUS; NERVE CELL LESION; NERVE DEGENERATION; NEUROANATOMY; NEUROPATHOLOGY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VAGUS NERVE; ANATOMY AND HISTOLOGY; ANIMAL; NODOSE GANGLION; PATHOLOGY;

ANIMALS; HUMANS; NODOSE GANGLION; PARKINSON DISEASE; VAGUS NERVE;

EID: 84903998027     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5859     Document Type: Review

References (292)

1. Abbott RA, Cox M, Markus H, and Tomkins A. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr 46: 879-884, 1992.
2. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, and Ross GW. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57: 456-462, 2001.
3. Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, and Wood MJ. Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res 69: 337-342, 2011.
4. Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, and Cooper JM. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 42: 360-367, 2011.
5. Angyan L. Medullary-induced alterations in intracranial self-stimulation from the substantia nigra. Neurobiology (Bp) 2: 195-210, 1994.
6. Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, and Greene JG. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol 124: 665-680, 2012.
7. Arrasate M, Mitra S, Schweitzer ES, Segal MR, and Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431: 805-810, 2004.
8. Ashraf W, Pfeiffer R, Park F, Lof J, and Quigley EM. Constipation in Parkinson's Disease: Objective assessment and response to psyllium. Mov Disord 12: 946-951, 1997.
9. Ashraf W, Wszolek ZK, Pfeiffer RF, Normand M, Maurer K, Srb F, Edwards LL, and Quigley EM. Anorectal function in fluctuating (on-off) Parkinson's disease: Evaluation by combined anorectal manometry and electromyography. Mov Disord 10: 650-657, 1995.
10. Astarloa R, Mena M, Sanchez V, de la Vega L, and de Yebenes J. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 15: 375-380, 1992.
11. Astrup J, Sorensen PM, and Sorensen HR. Oxygen and glucose consumption related to Na +-K + transport in canine brain. Stroke 12: 726-730, 1981.
12. Aziz NA, van der Marck MA, Pijl H, Olde Rikkert MG, Bloem BR, and Roos RA. Weight loss in neurodegenerative disorders. J Neurol 255: 1872-1880, 2008.
13. Banati RB, Daniel SE, and Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 13: 221-227, 1998.
14. Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, Bautista V, Poza YPM, Fernandez-Barreiro A, Hirsch EC, and Herrero MT. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46: 402-409, 2004.
15. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, and Daly MJ. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40: 955-962, 2008.
16. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL, 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, and Walker DG. Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117: 613-634, 2009.
17. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, and Walker DG. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 119: 689-702, 2010.
18. Benarroch EE. The central autonomic network: Functional organization, dysfunction, and perspective. Mayo Clin Proc 68: 988-1001, 1993.
19. Benarroch EE, Schmeichel AM, and Parisi JE. Involvement of the ventrolateral medulla in parkinsonism with autonomic failure. Neurology 54: 963-968, 2000.
20. Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, Tsiperson V, Nemachek C, Ciborowski P, Przedborski S, Mosley RL, and Gendelman HE. Nitrated alphasynuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One 3: E1376, 2008.
21. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, and Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455, 1973.
22. Berthoud HR, Carlson NR, and Powley TL. Topography of efferent vagal innervation of the rat gastrointestinal tract. Am J Physiol 260: R200-R207, 1991.
23. Bertrand E, Lechowicz W, Szpak GM, Lewandowska E, Dymecki J, and Wierzba-Bobrowicz T. Limbic neuropathology in idiopathic Parkinson's disease with concomitant dementia. Folia Neuropathol 42: 141-150, 2004.
24. Betarbet R, Sherer TB, and Greenamyre JT. Ubiquitinproteasome system and Parkinson's diseases. Exp Neurol 191 Suppl 1: S17-S27, 2005.
25. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, and Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306, 2000.
26. Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Juzwiak S, Kurzawski G, Tan EK, and Drozdzik M. CARD15 variants in patients with sporadic Parkinson's disease. Neurosci Res 57: 473-476, 2007.
27. Bindoff LA, Birch-Machin M, Cartlidge NE, Parker WD, Jr., and Turnbull DM. Mitochondrial function in Parkinson's disease. Lancet 2: 49, 1989.
28. Bjarnason IT, Charlett A, Dobbs RJ, Dobbs SM, Ibrahim MA, Kerwin RW, Mahler RF, Oxlade NL, Peterson DW, Plant JM, Price AB, and Weller C. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: Response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, doubleblind, placebo-controlled efficacy study. Helicobacter 10: 276-287, 2005.
29. Boldogh IR and Pon LA. Mitochondria on the move. Trends Cell Biol 17: 502-510, 2007.
30. Bordia T, Parameswaran N, Fan H, Langston JW, McIntosh JM, and Quik M. Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine. J Pharmacol Exp Ther 319: 285-292, 2006.
31. Borland MK, Trimmer PA, Rubinstein JD, Keeney PM, Mohanakumar K, Liu L, and Bennett JP, Jr. Chronic, lowdose rotenone reproduces Lewy neurites found in early stages of Parkinson's disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol Neurodegener 3: 21, 2008.
32. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, and Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458-462, 2000.
33. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, and Del Tredici K. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 21: 2042-2051, 2006.
34. Braak H, de Vos RA, Bohl J, and Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 396: 67-72, 2006.
35. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211, 2003.
36. Braak H, Rub U, Gai WP, and Del Tredici K. Idiopathic Parkinson's disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110: 517-536, 2003.
37. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, Bonduelle O, Alvarez-Fischer D, Callebert J, Launay JM, Duyckaerts C, Flavell RA, Hirsch EC, and Hunot S. Infiltration of CD4 + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 119: 182-192, 2009.
38. Bronstein DM, Perez-Otano I, Sun V, Mullis Sawin SB, Chan J, Wu GC, Hudson PM, Kong LY, Hong JS, and McMillian MK. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res 704: 112-116, 1995.
39. Brown P. Abnormal oscillatory synchronisation in the motor system leads to impaired movement. Curr Opin Neurobiol 17: 656-664, 2007.
40. Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, and Di Lazzaro V. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease. J Neurosci 21: 1033-1038, 2001.
41. Burke RE, Dauer WT, and Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 64: 485-491, 2008.
42. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, and Kopin IJ. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546-4550, 1983.
43. Cai QQ, Zheng LF, Fan RF, Lian H, Zhou L, Song HY, Tang YY, Feng XY, Guo ZK, Wang ZY, and Zhu JX. Distribution of dopamine receptors D1-and D2-immunoreactive neurons in the dorsal motor nucleus of vagus in rats. Auton Neurosci 176: 48-53, 2013.
44. Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebrooke RE, Di Monte DA, Emson PC, and Miller GW. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27: 8138-8148, 2007.
45. Cechetto DF. Central representation of visceral function. Fed Proc 46: 17-23, 1987.
46. Cechetto DF and Saper CB. Evidence for a viscerotopic sensory representation in the cortex and thalamus in the rat. J Comp Neurol 262: 27-45, 1987.
47. Chan CS, Gertler TS, and Surmeier DJ. Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci 32: 249-256, 2009.
48. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, and Surmeier DJ. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447: 1081-1086, 2007.
49. Charles PD, Van Blercom N, Krack P, Lee SL, Xie J, Besson G, Benabid AL, and Pollak P. Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 59: 932-934, 2002.
50. Chen CL, Lin HH, Chen SY, and Lin SZ. Utility of electrogastrography in differentiating Parkinson's disease with or without gastrointestinal symptoms: A prospective controlled study. Digestion 71: 187-191, 2005.
51. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, and Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58: 963-967, 2005.
52. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, and Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60: 1059-1064, 2003.
53. Cheyuo C, Jacob A, Wu R, Zhou M, Coppa GF, and Wang P. The parasympathetic nervous system in the quest for stroke therapeutics. J Cereb Blood Flow Metab 31: 1187-1195, 2011.
54. Chiba T, Kayahara T, and Nakano K. Efferent projections of infralimbic and prelimbic areas of the medial prefrontal cortex in the Japanese monkey, Macaca fuscata. Brain Res 888: 83-101, 2001.
55. This reference has been deleted.
56. Chung CY, Koprich JB, Siddiqi H, and Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alphasynucleinopathy. J Neurosci 29: 3365-3373, 2009.
57. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, and Isacson O. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14: 1709-1725, 2005.
58. Cochiolo JA, Ehsanian R, and Bruck DK. Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: Evidence of compensatory plasticity in nigrostriatal neurons. J Neurosci Res 59: 126-135, 2000.
59. Connor DE, Jr., Nixon M, Nanda A, and Guthikonda B. Vagal nerve stimulation for the treatment of medically refractory epilepsy: A review of the current literature. Neurosurg Focus 32: E12, 2012.
60. Cookson MR and van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 209: 5-11, 2008.
61. Costa RM, Lin SC, Sotnikova TD, Cyr M, Gainetdinov RR, Caron MG, and Nicolelis MA. Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron 52: 359-369, 2006.
62. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C, Hyman BT, and McLean PJ. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J 25: 326-336, 2011.
63. Darbin O and Wichmann T. Effects of striatal GABA Areceptor blockade on striatal and cortical activity in monkeys. J Neurophysiol 99: 1294-1305, 2008.
64. Dauer W and Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 39: 889-909, 2003.
65. Davey GP, Peuchen S, and Clark JB. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J Biol Chem 273: 12753-12757, 1998.
66. Davies KN, King D, Billington D, and Barrett JA. Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease. Postgrad Med J 72: 164-167, 1996.
67. de Jong W, Linthorst AC, and Versteeg HG. The nigrostriatal dopamine system and the development of hypertension in the spontaneously hypertensive rat. Arch Mal Coeur Vaiss 88: 1193-1196, 1995.
68. De Vos KJ, Grierson AJ, Ackerley S, and Miller CC. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 31: 151-173, 2008.
69. Dejean C, Gross CE, Bioulac B, and Boraud T. Dynamic changes in the cortex-basal ganglia network after dopamine depletion in the rat. J Neurophysiol 100: 385-396, 2008.
70. Dejean C, Hyland B, and Arbuthnott G. Cortical effects of subthalamic stimulation correlate with behavioral recovery from dopamine antagonist induced akinesia. Cereb Cortex 19: 1055-1063, 2009.
71. Delong M and Juncos J. Parkinson's disease and other movement disorders. In: Harrison's Principles of Internal Medicine, edited by Kasper DL. New York: McGraw-Hill Medical, 2004, pp. 2406-2418.
72. Derkinderen P, Rouaud T, Lebouvier T, Bruley des Varannes S, Neunlist M, De and Giorgio R. Parkinson disease: The enteric nervous system spills its guts. Neurology 77: 1761-1767, 2011.
73. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, and Lee SJ. Inclusion formation and neuronal cell death through neuron-toneuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 106: 13010-13015, 2009.
74. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, and Anandatheerthavarada HK. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283: 9089-9100, 2008.
75. Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H, Coron E, Bruley des Varannes S, Naveilhan P, Nguyen JM, Neunlist M, and Derkinderen P. Colonic inflammation in Parkinson's disease. Neurobiol Dis 50: 42-48, 2013.
76. Diamond B and Tracey KJ. Mapping the immunological homunculus. Proc Natl Acad Sci USA 108: 3461-3462, 2011.
77. Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, and Ahlskog JE. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 115: 437-444, 2008.
78. Djaldetti R, Achiron A, Ziv I, and Melamed E. First emergence of "delayed-on" and "dose failure" phenomena in a patient with Parkinson's disease following vagotomy. Mov Disord 9: 582-583, 1994.
79. Djaldetti R, Baron J, Ziv I, and Melamed E. Gastric emptying in Parkinson's disease: Patients with and without response fluctuations. Neurology 46: 1051-1054, 1996.
80. Djaldetti R, Ziv I, and Melamed E. Impaired absorption of oral levodopa: A major cause for response fluctuations in Parkinson's disease. Isr J Med Sci 32: 1224-1227, 1996.
81. Dobbs RJ, Dobbs SM, Weller C, Bjarnason IT, Oxlade NL, Charlett A, Al-Janabi MA, Kerwin RW, Mahler RF, and Price AB. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: Eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 10: 267-275, 2005.
82. Eadie MJ. The pathology of certain medullary nuclei in parkinsonism. Brain 86: 781-792, 1963.
83. Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, and Balluff M. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 6: 151-156, 1991.
84. Edwards LL, Quigley EM, Harned RK, Hofman R, and Pfeiffer RF. Characterization of swallowing and defecation in Parkinson's disease. Am J Gastroenterol 89: 15-25, 1994.
85. Edwards LL, Quigley EM, and Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: Frequency and pathophysiology. Neurology 42: 726-732, 1992.
86. Fearnley JM and Lees AJ. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114 (Pt 5): 2283-2301, 1991.
87. Filion M. Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey. Brain Res 178: 425-441, 1979.
88. Foix C and Nicolesco J. Anatomie Cerebrale: Les Noyaux Gris Centraux et la Region Mesencephalo-soux-optique. Pairs: Masson, 1925.
89. Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, and Keshavarzian A. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 6: E28032, 2011.
90. Francois C, Tande D, Yelnik J, and Hirsch EC. Distribution and morphology of nigral axons projecting to the thalamus in primates. J Comp Neurol 447: 249-260, 2002.
91. Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, Hartley M, Trevino I, O'Brien DE, Casey B, Goldberg MS, and Tansey MG. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 28: 10825-10834, 2008.
92. Fudge JL, Breitbart MA, Danish M, and Pannoni V. Insular and gustatory inputs to the caudal ventral striatum in primates. J Comp Neurol 490: 101-118, 2005.
93. Fujishiro H, Frigerio R, Burnett M, Klos KJ, Josephs KA, Delledonne A, Parisi JE, Ahlskog JE, and Dickson DW. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 23: 1085-1092, 2008.
94. Gai WP, Blessing WW, and Blumbergs PC. Ubiquitinpositive degenerating neurites in the brainstem in Parkinson's disease. Brain 118 (Pt 6): 1447-1459, 1995.
95. Gai WP, Blumbergs PC, Geffen LB, and Blessing WW. Age-related loss of dorsal vagal neurons in Parkinson's disease. Neurology 42: 2106-2111, 1992.
96. Gai WP, Geffen LB, Denoroy L, and Blessing WW. Loss of C1 and C3 epinephrine-synthesizing neurons in the medulla oblongata in Parkinson's disease. Ann Neurol 33: 357-367, 1993.
97. Galvin JE, Uryu K, Lee VM, and Trojanowski JQ. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci USA 96: 13450-13455, 1999.
98. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, and Lee VM. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28: 7687-7698, 2008.
99. Gao HM, Liu B, Zhang W, and Hong JS. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: Relevance to the etiology of Parkinson's disease. FASEB J 17: 1957-1959, 2003.
100. Gao HM, Zhang F, Zhou H, Kam W, Wilson B, and Hong JS. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect 119: 807-814, 2011.
101. Gatev P, Darbin O, and Wichmann T. Oscillations in the basal ganglia under normal conditions and in movement disorders. Mov Disord 21: 1566-1577, 2006.
102. Gatev P and Wichmann T. Interactions between cortical rhythms and spiking activity of single basal ganglia neurons in the normal and parkinsonian state. Cereb Cortex 19: 1330-1344, 2009.
103. German DC, Manaye KF, Sonsalla PK, and Brooks BA. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: Sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci 648: 42-62, 1992.
104. German DC, Manaye KF, White CL, 3rd, Woodward DJ, McIntire DD, Smith WK, Kalaria RN, and Mann DM. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32: 667-676, 1992.
105. Ghashghaei HT and Barbas H. Neural interaction between the basal forebrain and functionally distinct prefrontal cortices in the rhesus monkey. Neuroscience 103: 593-614, 2001.
106. Goetze O, Nikodem AB, Wiezcorek J, Banasch M, Przuntek H, Mueller T, Schmidt WE, and Woitalla D. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil 18: 369-375, 2006.
107. Goetze O, Wieczorek J, Mueller T, Przuntek H, Schmidt WE, and Woitalla D. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13Csodium octanoate breath test. Neurosci Lett 375: 170-173, 2005.
108. Goldberg JA, Guzman JN, Estep CM, Ilijic E, Kondapalli J, Sanchez-Padilla J, and Surmeier DJ. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat Neurosci 15: 1414-1421, 2012.
109. Goldstein AY, Wang X, and Schwarz TL. Axonal transport and the delivery of pre-synaptic components. Curr Opin Neurobiol 18: 495-503, 2008.
110. Goldstein DS. Cardiac denervation in patients with Parkinson disease. Cleve Clin J Med 74 Suppl 1: S91-S94, 2007.
111. Goldstein DS, Sharabi Y, Karp BI, Bentho O, Saleem A, Pacak K, and Eisenhofer G. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin Auton Res 17: 118-121, 2007.
112. Gravante G, Sabatino M, Caravaglios G, and La Grutta V. Nigral influence on intestinal activity in the cat. Acta Neurol (Napoli) 10: 231-238, 1988.
113. Greene JG. Gene expression profiles of brain dopamine neurons and relevance to neuropsychiatric disease. J Physiol 575: 411-416, 2006.
114. Greene JG, Dingledine R, and Greenamyre JT. Gene expression profiling of rat midbrain dopamine neurons: Implications for selective vulnerability in parkinsonism. Neurobiol Dis 18: 19-31, 2005.
115. Greene JG, Noorian AR, and Srinivasan S. Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp Neurol 218: 154-161, 2009.
116. Guerci B, Bourgeois C, Bresler L, Scherrer ML, and Bohme P. Gastric electrical stimulation for the treatment of diabetic gastroparesis. Diabetes Metab 38: 393-402, 2012.
117. Haack DG, Baumann RJ, McKean HE, Jameson HD, and Turbek JA. Nicotine exposure and Parkinson disease. Am J Epidemiol 114: 191-200, 1981.
118. Haber SN, Kunishio K, Mizobuchi M, and Lynd-Balta E. The orbital and medial prefrontal circuit through the primate basal ganglia. J Neurosci 15: 4851-4867, 1995.
119. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, and Geffen LB. Loss of brainstem serotonin-and substance P-containing neurons in Parkinson's disease. Brain Res 510: 104-107, 1990.
120. Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, Howe PR, Blessing WW, and Geffen LB. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 27: 373-385, 1990.
121. Hammond C, Bergman H, and Brown P. Pathological synchronization in Parkinson's disease: Networks, models and treatments. Trends Neurosci 30: 357-364, 2007.
122. Han YF and Cao GW. Role of nuclear receptor NR4A2 in gastrointestinal inflammation and cancers. World J Gastroenterol 18: 6865-6873, 2012.
123. Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, and Brundin P. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 121: 715-725, 2011.
124. Hansen C and Li JY. Beyond alpha-synuclein transfer: Pathology propagation in Parkinson's disease. Trends Mol Med 18: 248-255, 2012.
125. Hardoff R, Sula M, Tamir A, Soil A, Front A, Badarna S, Honigman S, and Giladi N. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 16: 1041-1047, 2001.
126. Hassler R. Zur Normalanatomie der Substantia nigra. Versuch einer architektonischen Gliederung. J Psych Neurol 48: 1-55, 1937.
127. Heimer G, Bar-Gad I, Goldberg JA, and Bergman H. Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism. J Neurosci 22: 7850-7855, 2002.
128. Hely MA, Morris JG, Reid WG, and Trafficante R. Sydney Multicenter Study of Parkinson's disease: Non-Ldopa-responsive problems dominate at 15 years. Mov Disord 20: 190-199, 2005.
129. Herkenham M, Little MD, Bankiewicz K, Yang SC, Markey SP, and Johannessen JN. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: An in vivo autoradiographic study. Neuroscience 40: 133-158, 1991.
130. Hinault MP, Farina-Henriquez-Cuendet A, and Goloubinoff P. Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease. Neurodegener Dis 8: 397-412, 2011.
131. Hirsch E, Graybiel AM, and Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334: 345-348, 1988.
132. Hirsch EC and Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection Lancet Neurol 8: 382-397, 2009.
133. Hoeger S, Bergstraesser C, Selhorst J, Fontana J, Birck R, Waldherr R, Beck G, Sticht C, Seelen MA, van Son WJ, Leuvenink H, Ploeg R, Schnuelle P, and Yard BA. Modulation of brain dead induced inflammation by vagus nerve stimulation. Am J Transplant 10: 477-489, 2010.
134. Holmberg B, Corneliusson O, and Elam M. Bilateral stimulation of nucleus subthalamicus in advanced Parkinson's disease: No effects on, and of, autonomic dysfunction. Mov Disord 20: 976-981, 2005.
135. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, and Masliah E. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157: 401-410, 2000.
136. Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H, Liu Y, Qian L, Wilson B, Di Monte DA, Ali SF, Zhang J, Block ML, and Hong JS. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol 181: 7194-7204, 2008.
137. Huston JM, Ochani M, Rosas-Ballina M, Liao H, Ochani K, Pavlov VA, Gallowitsch-Puerta M, Ashok M, Czura CJ, Foxwell B, Tracey KJ, and Ulloa L. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 203: 1623-1628, 2006.
138. Ito S and Craig AD. Striatal projections of the vagalresponsive region of the thalamic parafascicular nucleus in macaque monkeys. J Comp Neurol 506: 301-327, 2008.
139. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, and Takahashi H. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 52: 1269-1271, 1999.
140. Jang H, Boltz D, Sturm-Ramirez K, Shepherd KR, Jiao Y, Webster R, and Smeyne RJ. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci USA 106: 14063-14068, 2009.
141. Javitch JA, D'Amato RJ, Strittmatter SM, and Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite Nmethyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173-2177, 1985.
142. Johnson LR. Gastrointestinal Physiology. St. Louis: Mosby, Inc., 2001.
143. Jost WH and Schrank B. Defecatory disorders in de novo Parkinsonians-colonic transit and electromyogram of the external anal sphincter. Wien Klin Wochenschr 110: 535-537, 1998.
144. Kalaitzakis ME, Graeber MB, Gentleman SM, and Pearce RK. Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol 116: 125-128; author reply 129-131, 2008.
145. Kalaitzakis ME, Graeber MB, Gentleman SM, and Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: A critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 34: 284-295, 2008.
146. Kann O and Kovacs R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol 292: C641-C657, 2007.
147. Kashihara K. Weight loss in Parkinson's disease. J Neurol 253 Suppl 7: VII38-VII41, 2006.
148. Kawamata J, Suzuki S, and Shimohama S. Alpha7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease. Curr Drug Targets 13: 623-630, 2012.
149. Kessler, II and Diamond EL. Epidemiologic studies of Parkinson's disease. I. Smoking and Parkinson's disease: A survey and explanatory hypothesis. Am J Epidemiol 94: 16-25, 1971.
150. Komisaruk BR, Whipple B, Crawford A, Liu WC, Kalnin A, and Mosier K. Brain activation during vaginocervical self-stimulation and orgasm in women with complete spinal cord injury: FMRI evidence of mediation by the vagus nerves. Brain Res 1024: 77-88, 2004.
151. Kordower JH, Chu Y, Hauser RA, Freeman TB, and Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14: 504-506, 2008.
152. Kordower JH, Chu Y, Hauser RA, Olanow CW, and Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: A second case report. Mov Disord 23: 2303-2306, 2008.
153. Krygowska-Wajs A, Cheshire WP, Jr., Wszolek ZK, Hubalewska-Dydejczyk A, Jasinska-Myga B, Farrer MJ, Moskala M, and Sowa-Staszczak A. Evaluation of gastric emptying in familial and sporadic Parkinson disease. Parkinsonism Relat Disord 15: 692-696, 2009.
154. Kumaria A and Tolias CM. Is there a role for vagus nerve stimulation therapy as a treatment of traumatic brain injury Br J Neurosurg 26: 316-320, 2012.
155. Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, and Cote LJ. Parkinson's disease and megacolon: Concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 37: 1253-1255, 1987.
156. Kurlan R, Rothfield KP, Woodward WR, Nutt JG, Miller C, Lichter D, and Shoulson I. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology 38: 419-421, 1988.
157. Lach B, Grimes D, Benoit B, and Minkiewicz-Janda A. Caudate nucleus pathology in Parkinson's disease: Ultrastructural and biochemical findings in biopsy material. Acta Neuropathol 83: 352-360, 1992.
158. Ladabaum U, Minoshima S, Hasler WL, Cross D, Chey WD, and Owyang C. Gastric distention correlates with activation of multiple cortical and subcortical regions. Gastroenterology 120: 369-376, 2001.
159. Langston JW. The Parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann Neurol 59: 591-596, 2006.
160. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46: 598-605, 1999.
161. Lanotte M, Lopiano L, Torre E, Bergamasco B, Colloca L, and Benedetti F. Expectation enhances autonomic responses to stimulation of the human subthalamic limbic region. Brain Behav Immun 19: 500-509, 2005.
162. Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, and Vassilatis DK. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 33: 85-89, 2003.
163. Lebouvier T, Chaumette T, Damier P, Coron E, Touchefeu Y, Vrignaud S, Naveilhan P, Galmiche JP, Bruley des Varannes S, Derkinderen P, and Neunlist M. Pathological lesions in colonic biopsies during Parkinson's disease. Gut 57: 1741-1743, 2008.
164. Lebouvier T, Chaumette T, Paillusson S, Duyckaerts C, Bruley des Varannes S, Neunlist M, and Derkinderen P. The second brain and Parkinson's disease. Eur J Neurosci 30: 735-741, 2009.
165. Lebouvier T, Neunlist M, Bruley des Varannes S, Coron E, Drouard A, N'Guyen JM, Chaumette T, Tasselli M, Paillusson S, Flamand M, Galmiche JP, Damier P, and Derkinderen P. Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One 5: E12728, 2010.
166. Lee HJ, Khoshaghideh F, Lee S, and Lee SJ. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur J Neurosci 24: 3153-3162, 2006.
167. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, and Lee SJ. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285: 9262-9272, 2010.
168. Lee JK, McCoy MK, Harms AS, Ruhn KA, Gold SJ, and Tansey MG. Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. J Neurosci 28: 8517-8528, 2008.
169. Lees AJ. The Parkinson chimera. Neurology 72: S2-S11, 2009.
170. Levy R, Ashby P, Hutchison WD, Lang AE, Lozano AM, and Dostrovsky JO. Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain 125: 1196-1209, 2002.
171. Lewis SJ and Barker RA. Understanding the dopaminergic deficits in Parkinson's disease: Insights into disease heterogeneity. J Clin Neurosci 16: 620-625, 2009.
172. Lewy FH. Paralysis agitans. In: Pathologische Anatomie. Handbuch der Neurologie, edited by Lewandowsky M. Berlin: Springer-Verlag, 1912, pp. 920-923.
173. Lewy FH. Zur pathologischen anatomie der paralysis agitans. Dtsch Z Nervenheilkd 50: 50-55, 1913.
174. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, and Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14: 501-503, 2008.
175. Li JY, Henning Jensen P, and Dahlstrom A. Differential localization of alpha-, beta-and gamma-synucleins in the rat CNS. Neuroscience 113: 463-478, 2002.
176. Lin MT and Yang JJ. Stimulation of the nigrostriatal dopamine system produces hypertension and tachycardia in rats. Am J Physiol 266: H2489-H2496, 1994.
177. Linazasoro G. Classical Parkinson disease versus Parkinson complex-reflections against staging and in favour of heterogeneity. Eur J Neurol 14: 721-728, 2007.
178. Linthorst AC, van Giersbergen PL, Gras M, Versteeg DH, and de Jong W. The nigrostriatal dopamine system: Role in the development of hypertension in spontaneously hypertensive rats. Brain Res 639: 261-268, 1994.
179. Liu G, Zhang C, Yin J, Li X, Cheng F, Li Y, Yang H, Ueda K, Chan P, and Yu S. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci Lett 454: 187-192, 2009.
180. Loewy AD. Forebrain nuclei involved in autonomic control. Prog Brain Res 87: 253-268, 1991.
181. Lopshire JC and Zipes DP. Device therapy to modulate the autonomic nervous system to treat heart failure. Curr Cardiol Rep 14: 593-600, 2012.
182. Low PA and Bennaroch EE. (Eds). Clinical Autonomic Disorders. Philadelphia: Lippincott, Williams, and Wilkins, 2008.
183. Lu SF, Young HJ, and Lin MT. Nigrostriatal dopamine system mediates baroreflex sensitivity in rats. Neurosci Lett 190: 17-20, 1995.
184. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, and Lee VM. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338: 949-953, 2012.
185. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, and Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209: 975-986, 2012.
186. Macefield VG and Henderson LA. Real-time imaging of the medullary circuitry involved in the generation of spontaneous muscle sympathetic nerve activity in awake subjects. Hum Brain Mapp 31: 539-549, 2010.
187. Mahon S, Vautrelle N, Pezard L, Slaght SJ, Deniau JM, Chouvet G, and Charpier S. Distinct patterns of striatal medium spiny neuron activity during the natural sleepwake cycle. J Neurosci 26: 12587-12595, 2006.
188. Mallet N, Pogosyan A, Marton LF, Bolam JP, Brown P, and Magill PJ. Parkinsonian beta oscillations in the external globus pallidus and their relationship with subthalamic nucleus activity. J Neurosci 28: 14245-14258, 2008.
189. Mallet N, Pogosyan A, Sharott A, Csicsvari J, Bolam JP, Brown P, and Magill PJ. Disrupted dopamine transmission and the emergence of exaggerated beta oscillations in subthalamic nucleus and cerebral cortex. J Neurosci 28: 4795-4806, 2008.
190. Marinella MA. Acute colonic pseudo-obstruction complicated by cecal perforation in a patient with Parkinson's disease. South Med J 90: 1023-1026, 1997.
191. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, and Lee MK. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26: 41-50, 2006.
192. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, and Hasegawa M. Prion-like spreading of pathological alpha-synuclein in brain. Brain 136: 1128-1138, 2013.
193. McBride PA, Schulz-Schaeffer WJ, Donaldson M, Bruce M, Diringer H, Kretzschmar HA, and Beekes M. Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J Virol 75: 9320-9327, 2001.
194. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, and Tansey MG. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 26: 9365-9375, 2006.
195. McGeer PL, Schwab C, Parent A, and Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol 54: 599-604, 2003.
196. Miller N, Noble E, Jones D, and Burn D. Hard to swallow: Dysphagia in Parkinson's disease. Age Ageing 35: 614-618, 2006.
197. Morfini G, Pigino G, Opalach K, Serulle Y, Moreira JE, Sugimori M, Llinas RR, and Brady ST. 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc Natl Acad Sci USA 104: 2442-2447, 2007.
198. Morrison LA, Sidman RL, and Fields BN. Direct spread of reovirus from the intestinal lumen to the central nervous system through vagal autonomic nerve fibers. Proc Natl Acad Sci USA 88: 3852-3856, 1991.
199. Mougenot AL, Bencsik A, Nicot S, Vulin J, Morignat E, Verchere J, Betemps D, Lakhdar L, Legastelois S, and Baron TG. Transmission of prion strains in a transgenic mouse model overexpressing human A53T mutated alpha-synuclein. J Neuropathol Exp Neurol 70: 377-385, 2011.
200. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere J, Lakhdar L, Legastelois S, and Baron T. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 33: 2225-2228, 2012.
201. Muller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D, and Goetze O. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 29: 61-67, 2006.
202. Neafsey EJ. Prefrontal cortical control of the autonomic nervous system: Anatomical and physiological observations. Prog Brain Res 85: 147-165; discussion 165-166, 1990.
203. Nicklas WJ, Vyas I, and Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36: 2503-2508, 1985.
204. Nobrega AC, Rodrigues B, and Melo A. Is silent aspiration a risk factor for respiratory infection in Parkinson's disease patients Parkinsonism Relat Disord 14: 646-648, 2008.
205. Noorian AR, Rha J, Annerino DM, Bernhard D, Taylor GM, and Greene JG. Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system. Neurobiol Dis 48: 9-19, 2012.
206. Nosaka S, Yamamoto T, and Yasunaga K. Localization of vagal cardioinhibitory preganglionic neurons with rat brain stem. J Comp Neurol 186: 79-92, 1979.
207. Obeso JA, Jahanshahi M, Alvarez L, Macias R, Pedroso I, Wilkinson L, Pavon N, Day B, Pinto S, Rodriguez-Oroz MC, Tejeiro J, Artieda J, Talelli P, Swayne O, Rodriguez R, Bhatia K, Rodriguez-Diaz M, Lopez G, Guridi J, and Rothwell JC. What can man do without basal ganglia motor output The effect of combined unilateral subthalamotomy and pallidotomy in a patient with Parkinson's disease. Exp Neurol 220: 283-292, 2009.
208. Olofsson PS, Rosas-Ballina M, Levine YA, and Tracey KJ. Rethinking inflammation: Neural circuits in the regulation of immunity. Immunol Rev 248: 188-204, 2012.
209. Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, Tsuchiya K, Mori F, Wakabayashi K, and Takahashi H. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109: 583-588, 2005.
210. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, and Takahashi H. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 17: 24-30, 2007.
211. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, and Takahashi H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131: 642-650, 2008.
212. Parihar MS, Parihar A, Fujita M, Hashimoto M, and Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 65: 1272-1284, 2008.
213. Parihar MS, Parihar A, Fujita M, Hashimoto M, and Ghafourifar P. Alpha synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int J Biochem Cell Biol 41: 2015-2024, 2009.
214. Park HJ, Lee PH, Ahn YW, Choi YJ, Lee G, Lee DY, Chung ES, and Jin BK. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci 26: 79-89, 2007.
215. Parker WD, Jr., Boyson SJ, and Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-723, 1989.
216. Parkinson J. An Essay on the Shaking Palsy. London: Whittingham and Rowland, 1817.
217. Parkkinen L, Pirttila T, and Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115: 399-407, 2008.
218. Pathak RU and Davey GP. Complex I and energy thresholds in the brain. Biochim Biophys Acta 1777: 777-782, 2008.
219. Patrick A and Epstein O. Review article: Gastroparesis. Aliment Pharmacol Ther 27: 724-740, 2008.
220. Pavlov VA, Ochani M, Gallowitsch-Puerta M, Ochani K, Huston JM, Czura CJ, Al-Abed Y, and Tracey KJ. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci USA 103: 5219-5223, 2006.
221. Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, Chavan S, Al-Abed Y, and Tracey KJ. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun 23: 41-45, 2009.
222. Pavlov VA, Wang H, Czura CJ, Friedman SG, and Tracey KJ. The cholinergic anti-inflammatory pathway: A missing link in neuroimmunomodulation. Mol Med 9: 125-134, 2003.
223. Pazo JH and Belforte JE. Basal ganglia and functions of the autonomic nervous system. Cell Mol Neurobiol 22: 645-654, 2002.
224. Pazo JH, Gomez-Gonzales M, Tumilasci OR, O'Donnell P, and Murer G. The sialagogue response of striatal dopamine receptors to L-dopa is not influenced by castration or chronic estrogen treatment. Brain Res Bull 16: 1-4, 1986.
225. Pazo JH, Medina JH, and Tumilasci OR. The role of the caudate-putamen nucleus in salivary secretion induced by L-DOPA. Neuropharmacology 21: 261-265, 1982.
226. Pearce JM. The Lewy body. J Neurol Neurosurg Psychiatry 71: 214, 2001.
227. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2: 107-116, 2003.
228. Pfeiffer RF and Quigley EM. Gastrointestinal motility problems in patients with Parkinson's disease: Epidemiology, pathophysiology, and guidelines for management. CNS Drugs 11: 435-448, 1999.
229. Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, and Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: Autonomic pathway implicated in Parkinson's disease Neuroscience 153: 733-750, 2008.
230. Poewe W. Nonmotor symptoms in Parkinson's disease. In: Parkinson's Disease and Movement Disorders, edited by Janckovic J and Tolosa E. Philadelphia, PA: Lippincott, Wilkins, and Williams, 2007, pp. 67-76.
231. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, and Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047, 1997.
232. Pouclet H, Lebouvier T, Coron E, Des Varannes SB, Neunlist M, and Derkinderen P. A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson's disease. Neurogastroenterol Motil 24: E202-e205, 2012.
233. Powers KM, Kay DM, Factor SA, Zabetian CP, Higgins DS, Samii A, Nutt JG, Griffith A, Leis B, Roberts JW, Martinez ED, Montimurro JS, Checkoway H, and Payami H. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord 23: 88-95, 2008.
234. Powley TL and Phillips RJ. Musings on the wanderer: What's new in our understanding of vago-vagal reflexes I. Morphology and topography of vagal afferents innervating the GI tract. Am J Physiol Gastrointest Liver Physiol 283: G1217-G1225, 2002.
235. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, Knapp DJ, and Crews FT. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453-462, 2007.
236. Qualman SJ, Haupt HM, Yang P, and Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology 87: 848-856, 1984.
237. Quigley EM. Gastric motor and sensory function and motor disorders of the stomach. In: Sleisenger & Fordtran's Gastrointestinal and Liver Disease Pathophysiology/Diagnosis/Management, edited by Friedman LS, Brandt LJ, and Feldman M. Philadelphia: Elsevier, 2006, pp. 999-1028.
238. Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A, Kim A, Tyndale RF, Langston JW, and Di Monte DA. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem 98: 1866-1875, 2006.
239. Raz A, Feingold A, Zelanskaya V, Vaadia E, and Bergman H. Neuronal synchronization of tonically active neurons in the striatum of normal and parkinsonian primates. J Neurophysiol 76: 2083-2088, 1996.
240. Read SJ, Leggett BA, and Pender MP. Gastroparesis with multiple sclerosis. Lancet 346: 1228, 1995.
241. Reddymasu SC, Bonino J, and McCallum RW. Gastroparesis secondary to a demyelinating disease: A case series. BMC Gastroenterol 7: 3, 2007.
242. Reynolds AD, Banerjee R, Liu J, Gendelman HE, and Mosley RL. Neuroprotective activities of CD4 + CD25 + regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol 82: 1083-1094, 2007.
243. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, and Gendelman HE. Regulatory T cells attenuate th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol 184: 2261-2271, 2010.
244. Rinne OJ, Nurmi E, Ruottinen HM, Bergman J, Eskola O, and Solin O. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse 40: 193-200, 2001.
245. Rizvi SJ, Donovan M, Giacobbe P, Placenza F, Rotzinger S, and Kennedy SH. Neurostimulation therapies for treatment resistant depression: A focus on vagus nerve stimulation and deep brain stimulation. Int Rev Psychiatry 23: 424-436, 2011.
246. Rosas-Ballina M, Ochani M, Parrish WR, Ochani K, Harris YT, Huston JM, Chavan S, and Tracey KJ. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci USA 105: 11008-11013, 2008.
247. Rosas-Ballina M, Olofsson PS, Ochani M, Valdes-Ferrer SI, Levine YA, Reardon C, Tusche MW, Pavlov VA, Andersson U, Chavan S, Mak TW, and Tracey KJ. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 334: 98-101, 2011.
248. Rosas-Ballina M and Tracey KJ. The neurology of the immune system: Neural reflexes regulate immunity. Neuron 64: 28-32, 2009.
249. Rosin B, Nevet A, Elias S, Rivlin-Etzion M, Israel Z, and Bergman H. Physiology and pathophysiology of the basal ganglia-thalamo-cortical networks. Parkinsonism Relat Disord 13 Suppl 3: S437-S439, 2007.
250. Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, and Hattori T. Questionnairebased assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 92: 76-85, 2001.
251. Sakakibara R, Uchiyama T, Yamanishi T, Shirai K, and Hattori T. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm 115: 443-460, 2008.
252. Salat-Foix D, Tran K, Ranawaya R, Meddings J, and Suchowersky O. Increased intestinal permeability and Parkinson disease patients: Chicken or egg Can J Neurol Sci 39: 185-188, 2012.
253. Samii A, Etminan M, Wiens MO, and Jafari S. NSAID use and the risk of Parkinson's disease: Systematic review and meta-analysis of observational studies. Drugs Aging 26: 769-779, 2009.
254. Schaller BJ, Graf R, and Jacobs AH. Pathophysiological changes of the gastrointestinal tract in ischemic stroke. Am J Gastroenterol 101: 1655-1665, 2006.
255. Sharott A, Magill PJ, Harnack D, Kupsch A, Meissner W, and Brown P. Dopamine depletion increases the power and coherence of beta-oscillations in the cerebral cortex and subthalamic nucleus of the awake rat. Eur J Neurosci 21: 1413-1422, 2005.
256. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, and Pfeiffer RF. Autonomic dysfunction in Parkinson's disease: A comprehensive symptom survey. Parkinsonism Relat Disord 8: 277-284, 2002.
257. Singer C, Weiner WJ, and Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson's disease. Eur Neurol 32: 134-140, 1992.
258. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, and Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841, 2003.
259. Smith Y, Raju DV, Pare JF, and Sidibe M. The thalamostriatal system: A highly specific network of the basal ganglia circuitry. Trends Neurosci 27: 520-527, 2004.
260. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388: 839-840, 1997.
261. Sulzer D and Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord 28: 41-50, 2013.
262. Tansey MG and Goldberg MS. Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37: 510-518, 2010.
263. Tansey MG, McCoy MK, and Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208: 1-25, 2007.
264. Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, Iuvone PM, Weinshenker D, Greene JG, and Miller GW. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 29: 8103-8113, 2009.
265. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100: 5473-5478, 2003.
266. Temlett JA and Thompson PD. Reasons for admission to hospital for Parkinson's disease. Intern Med J 36: 524-526, 2006.
267. Tobi M, Holtz T, Carethers J, and Owyang C. Delayed gastric emptying after laparoscopic anterior highly selective and posterior truncal vagotomy. Am J Gastroenterol 90: 810-811, 1995.
268. Travagli RA, Hermann GE, Browning KN, and Rogers RC. Brainstem circuits regulating gastric function. Annu Rev Physiol 68: 279-305, 2006.
269. Ueki A and Otsuka M. Life style risks of Parkinson's disease: Association between decreased water intake and constipation. J Neurol 251 Suppl 7: VII18-vII23, 2004.
270. Uematsu A, Tsurugizawa T, Uneyama H, and Torii K. Brain-gut communication via vagus nerve modulates conditioned flavor preference. Eur J Neurosci 31: 1136-1143, 2010.
271. Undem BJ and Carr MJ. Targeting primary afferent nerves for novel antitussive therapy. Chest 137: 177-184, 2010.
272. Van Laar VS and Berman SB. Mitochondrial dynamics in Parkinson's disease. Exp Neurol 218: 247-256, 2009.
273. Villaran RF, Espinosa-Oliva AM, Sarmiento M, De Pablos RM, Arguelles S, Delgado-Cortes MJ, Sobrino V, Van Rooijen N, Venero JL, Herrera AJ, Cano J, and Machado A. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: Potential risk factor in Parkinson's disease. J Neurochem 114: 1687-1700, 2010.
274. Vorobyov VV, Schibaev NV, Morelli M, and Carta AR. EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res 972: 177-185, 2003.
275. Wakabayashi K, Takahashi H, Ohama E, and Ikuta F. Parkinson's disease: An immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol (Berl) 79: 581-583, 1990.
276. Wakabayashi K, Takahashi H, Takeda S, Ohama E, and Ikuta F. Parkinson's disease: The presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol (Berl) 76: 217-221, 1988.
277. Wakabayashi K, Takahashi H, Takeda S, Ohama E, and Ikuta F. Lewy bodies in the enteric nervous system in Parkinson's disease. Arch Histol Cytol 52 Suppl: 191-194, 1989.
278. Wakabayashi K, Toyoshima Y, Awamori K, Anezaki T, Yoshimoto M, Tsuji S, and Takahashi H. Restricted occurrence of Lewy bodies in the dorsal vagal nucleus in a patient with late-onset parkinsonism. J Neurol Sci 165: 188-191, 1999.
279. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, and Tracey KJ. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421: 384-388, 2003.
280. Weinberger M, Mahant N, Hutchison WD, Lozano AM, Moro E, Hodaie M, Lang AE, and Dostrovsky JO. Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol 96: 3248-3256, 2006.
281. Weller C, Charlett A, Oxlade NL, Dobbs SM, Dobbs RJ, Peterson DW, and Bjarnason IT. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 3: Predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile. Helicobacter 10: 288-297, 2005.
282. Whited KL, Hornof WJ, Garcia T, Bohan DC, Larson RF, and Raybould HE. A non-invasive method for measurement of gastric emptying in mice: Effects of altering fat content and CCK A receptor blockade. Neurogastroenterol Motil 16: 421-427, 2004.
283. Whited KL, Thao D, Lloyd KC, Kopin AS, and Raybould HE. Targeted disruption of the murine CCK1 receptor gene reduces intestinal lipid-induced feedback inhibition of gastric function. Am J Physiol Gastrointest Liver Physiol 291: G156-G162, 2006.
284. Wichmann T, Kliem MA, and Soares J. Slow oscillatory discharge in the primate basal ganglia. J Neurophysiol 87: 1145-1148, 2002.
285. Wichmann T and Soares J. Neuronal firing before and after burst discharges in the monkey Basal Ganglia is predictably patterned in the normal state and altered in parkinsonism. J Neurophysiol 95: 2120-2133, 2006.
286. Wishart TM, Parson SH, and Gillingwater TH. Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol 65: 733-739, 2006.
287. Woodford H and Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. Mov Disord 20: 1104-1108, 2005.
288. Yang H, Antoine DJ, Andersson U, and Tracey KJ. The many faces of HMGB1: Molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 93: 865-873, 2013.
289. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME, Al-Abed Y, Andersson U, Tracey KJ, and Antoine DJ. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 18: 250-259, 2012.
290. Yao Z and Wood NW. Cell death pathways in Parkinson's disease: Role of mitochondria. Antioxid Redox Signal 11: 2135-2149, 2009.
291. Zheng LF, Zhang Y, Chen CL, Song J, Fan RF, Cai QQ, Wang ZY, and Zhu JX. Alterations in TH-and ChATimmunoreactive neurons in the DMV and gastric dysmotility in an LPS-induced PD rat model. Auton Neurosci 177: 194-198, 2013.
292. Zibetti M, Torre E, Cinquepalmi A, Rosso M, Ducati A, Bergamasco B, Lanotte M, and Lopiano L. Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. Eur Neurol 58: 218-223, 2007.